Viking Therapeut

VKTX NASDAQ
7.07
-0.05
-0.70%
交易中 14:11 08/22 EDT
开盘
7.13
昨收
7.12
最高
7.14
最低
6.94
成交量
47.54万
成交均量(3M)
133.66万
52周最高
24.00
52周最低
6.53
换手率
0.66%
市值
5.11亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Viking Therapeut VKTX股票价格,Viking Therapeut股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.
展开 >

最近浏览

名称
价格
涨跌幅